Is JAZZ or JBIO more undervalued in 2026?

CirclFi compares Jazz Pharmaceuticals plc (JAZZ) and Jade Biosciences, Inc. (JBIO) using 13 institutional-grade valuation models. JAZZ has a Quality of Company score of 7.5/10 while JBIO scores 4.1/10.

Which is a better buy — JAZZ or JBIO?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do JAZZ and JBIO valuations compare?

JAZZ at $235.38 and JBIO at $20.84 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

JAZZ vs JBIO Valuation Comparison 2026 — Intrinsic Value Analysis

JAZZ

Biotechnology

Jazz Pharmaceuticals plc

Quality

7.5

out of 10

Value Trap

SAFE

Price

$235.38

Last close

Models

12/13

Active

JBIO

Biotechnology

Jade Biosciences, Inc.

Quality

4.1

out of 10

Value Trap

SAFE

Price

$20.84

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	JAZZ Fair Value	JAZZ Upside	JBIO Fair Value	JBIO Upside
Bayesian DCF	Intrinsic	$399.99	+69.9%	$5.78	-72.3%
EROIC Spread	Intrinsic	$108.93	-44.6%	—	—
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$27.12	-88.5%	$3.86	-81.5%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for JAZZ vs JBIO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

JAZZ vs JBIO — Which Stock Is More Undervalued?

JAZZ scores higher with a 7.5/10 quality rating vs JBIO's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Jazz Pharmaceuticals plc (JAZZ) and Jade Biosciences, Inc. (JBIO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

JAZZ currently trades at $235.38 with a QOC of 7.5/10, while JBIO trades at $20.84 with a QOC of 4.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).